Gene expression profiling in ANCA-vasculitis renal biopsies

Similar documents
New biomarkers for ANCA-associated Vasculitis? Juliana Bordignon Draibe

ANCA associated vasculitis in China

Complement in vasculitis and glomerulonephritis. Andy Rees Clinical Institute of Pathology Medical University of Vienna

Histopathology: Glomerulonephritis and other renal pathology

Renal Pathology Case Conference. Case 2

DC were seeded into tissue culture dishes in IMDM 2% FCS, and added with PMN. (1:1; PMN: DC) for 16h also in the presence of DNAse (100 U/ml); DC were

Updates from the 15 th ANCA workshop

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Dr Ian Roberts Oxford

EUVAS update June 5 th Marinka Twilt

Membranous nephropathy. By Mohammed Kamal Nassar, MD Lecturer of Nephrology Mansoura University

Management and treatment of glomerular diseases KDIGO Controversies Conference Part 1

Case # 2 3/27/2017. Disclosure of Relevant Financial Relationships. Clinical history. Clinical history. Laboratory findings

SHO Teaching. Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth

SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018

Intermediate monocytes in ANCA vasculitis: increased surface. expression of ANCA autoantigens and IL-1β secretion in response. to anti-mpo antibodies

SCOTTISH REAL BIOPSY REGISTRY: SURVEY OF NATIVE KIDNEY BIOPSY IN SCOTLAND 2015

Management of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe

n BASIC-TRANSLATIONAL REVIEW

Atypical IgA Nephropathy

CHAPTER 2. Primary Glomerulonephritis

Year 2004 Paper one: Questions supplied by Megan

C1q nephropathy the Diverse Disease

C3G An Update What is C3 Glomerulopathy Anyway? Patrick D. Walker, M.D. Nephropath Little Rock, Arkansas USA

EULAR/ERA-EDTA recommendations for the management of ANCAassociated

Plasma exchanges in ANCA-associated vasculitis

Clinical Study Glomerulonephritis with Crescents in Children: Etiology and Predictors of Renal Outcome

PR3/MPO-ANCA is as effective as immunofluorescence as a first-line test in AAV screening

A clinical syndrome, composed mainly of:

CHAPTER 2 PRIMARY GLOMERULONEPHRITIS

University of Groningen. Hidradenitis suppurativa Dickinson-Blok, Janine Louise

Willcocks et al.,

29th Annual Meeting of the Glomerular Disease Collaborative Network

Enterprise Interest None

Journal of Nephropathology

Rapidly progressive glomerulonephritis. Alan Salama UCL Centre for Nephrology Royal Free Hospital

Simultaneous comprehensive multiplex autoantibody analysis by CytoBead technology for Rapidly Progressive Glomerulonephritis.

Elevated Serum Creatinine, a simplified approach

MICROSCOPIC HEMATURIA AND DIFFUSE NECROTIZING GLOMERULONEPHRITIS

CHAPTER 3. Secondary Glomerulonephritis

CHAPTER I INTRODUCTION. Nowadays chronic kidney disease (CKD) becomes one. of the most common diseases found in the population.

ANCA-associated vasculitis and organ-on-chips disease model

ExpressArt FFPE Clear RNAready kit

Is it Autoimmune or NOT! Presented to AONP! October 2015!

Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis

PRINCIPLE OF URINALYSIS

Genomics Core Facility of the University of Leicester Technical note March 2012

Tell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital

CHAPTER 3 SECONDARY GLOMERULONEPHRITIS

Anti-MPO ANCA-Associated Diffuse Alveolar Hemorrhage is Associated with Increased Mortality Compared to Anti-PR3 Disease

RATIONALE. K Without therapy, ANCA vasculitis with GN is associated. K There is high-quality evidence for treatment with

DIAGNOSTIC SLIDE SEMINAR: PART 1 RENAL TUMOUR BIOPSY CASES

Classification of Glomerular Diseases and Defining Individual Glomerular Lesions: Developing International Consensus

Introduction. 1. Introduction

Small Vessel Vasculitis

New Developments in ANCA-associated Vasculitis

Secondary IgA Nephropathy & HSP

Rituximab treatment for ANCA-associated vasculitis in childhood

Dual positive serology in a case of rapidly progressive glomerulonephritis in a middle aged woman

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS

Renal Biopsy Findings in Children Receiving Long-Term Treatment with Cyclosporine A Given as a Single Daily Dose

AN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS

Management of scleroderma renal crisis. Voon Ong Senior Clinical Lecturer Royal Free Hospital and UCL Medical School, London, UK

Year In Review: VasculitisPers. Disclosures. Learning Objectives. none 4/16/2018. Describe new medications for the treatment of vasculitis

EDITORIAL. Issue Seventeen, October Editorial Team. Issue Seventeen. Info link

Digitizing the Proteomes From Big Tissue Biobanks

CHAPTER 3. Secondary Glomerulonephritis

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody associated vasculitis

Pathogenesis of IgA Nephropathy. Shokoufeh Savaj MD Associate Professor of Medicine Firoozgar hospital- IUMS

Renal Pathology 1: Glomerulus. With many thanks to Elizabeth Angus PhD for EM photographs

Managing Acute Medical Problems, Birmingham Vasculitis. David Jayne. University of Cambridge

Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis

Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis

Disorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome.

Chapter 2 Animal Models of ANCA-Associated Vasculitides

Corporate Presentation January 2013

Monoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH

Acute (Tubulo-) Interstitial Nephritis (TIN)

MOLECULAR IMMUNOLOGY Manipulation of immune response Autoimmune diseases & the pathogenic mechanism

Biomarkers of immunity and inflammation for use in nutrition interventions: ILSI Europe work on selection criteria and interpretation

SKCC Protocol Review Committee New Study Application

Glomerular diseases mostly presenting with Nephritic syndrome

Additional file 2: Details of cohort studies and randomised trials

RENAL HISTOPATHOLOGY

New Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis

Redefining lupus nephritis: clinical implications of pathophysiologic subtypes

Renal manifestations of IgG4-related systemic disease

Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab

Diagnosis idili other ALI. definite highly likely probable possible unlikely. excluded excluded unlikely probable

Contents. Welcome to EULAR 2012 Berlin... iii AbstractsReviewers... iv. Speakers Abstracts

Monocyte subsets in health and disease. Marion Frankenberger

The effects of Cell Subset Isolation Method on Gene Expression inleukocytes

Biomarkers for Kidney Disease

Supplementary Figure Legends

Central tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response

Mechanisms of Immune Tolerance

N. Hiramatsu, T. Kuroiwa, H. Ikeuchi, A. Maeshima, Y. Kaneko, K. Hiromura, K. Ueki and Y. Nojima

Small Vessel Vasculitis

CHAPTER 4. Paediatric Renal Biopsies

Transcription:

Gene expression profiling in ANCA-vasculitis renal biopsies Marcia Friedman, MD Northwest Rheumatism Society Meeting OHSU Fellow Research Presentation April 29 th 2017

Disclosures I have no disclosures

Background Significant recent advancements in AAV pathophysiology highlighting the role of netosis, pathogenicity of ANCAs, and the alternative complement system as an amplification pathway in active disease. Little is known about the mechanism of disease damage at the endorgan level Gene expression analysis is an important tool to identify precise disease-specific treatment targets This project aims to apply this analysis technique to the study of the ANCA-associated vasculitis (AAV) kidney.

Gene expression profiling in AAV Whole blood, leukocytes, nasal brushings, orbital tissue, and renal tissues 1. RAVE study patients: whole blood during active disease and remission: 179 genes predominantly including granulocyte related genes, MPO, and PR3- paid particular attention to 11 genes selected to represent the spectrum of neutrophil granular proteins. Compared responders v non-responders; high levels of granulocyte gene expression predicted lower likelihood of treatment response. Arthritis Rheumatol. 2015 Jul;67(7):1922-32

Gene expression profiling in AAV 2. Nasal turbinate brushings from 32 GPA patients (10 active, 13 prior sinus disease, 9 no hx of nasal disease) 12 healthy, 15 sarcoid, 8 allergic rhinitis. Genes related to granulocyte and agranulocyte migration/adhesion, epithelial barrier integrity, IL10 signaling, and TREM1 signaling PR3 and MPO genes were not differentially expressed Differences between active/quiet GPA patients: 18 genes differentially expressed including genes involved in cell adhesion and matricellular proteins Arthritis Rheumatol. 2015 May; 67(8): 2233 2239.

Gene expression profiling in AAV 3. Leukocytes in AAV, SLE, and RA compared to healthy donors. Differential expression in AAV, SLE, and RA AAV genes involved in innate immunity, inflammatory processes, and stress/wounding genes. (TLR genes, B-cell lymphoma 6 gene, and IL-1 receptions I/II genes) Kidney Int. 2007 Oct;72(7):853-64.

4. AAV Renal Gene Expression: 2016 ACR Abstracts Eddy et al. Inflammatory pathways as shared molecular targets across AAV and nephrotic syndrome: Samples from NEPTUNE cohort and European Renal cdna Bank Searching for shared therapeutic targets of nephrotic syndrome: Tec Kinase, IL-8 signaling, TNF, IFNG, TGFB1, and NFkappaB Grayson et al. Immunometabolism in ANCA-associated GN: Samples from the European Renal cdna Bank and other groups Upregulation of pentose pathways (G6PD) and glycolysis regulatory genes. Downregulation of Krebs cycle, glutaminolysis, and fatty acid oxidation genes. Indicated metabolism of glucose as a novel treatment approach Both studies lack clinical data

4. AAV Renal Gene Expression 28 MPO-AAV Renal biopsies: evaluating genes expressed in ANCAvasculitis tubulointerstitial injury Tubulointerstitial injury severity correlated with IL-1beta expression. Also identified TLR4 and NLRP3 correlating with severity of injury Clin Nephrol. 2016 Oct;86(10):190-9.

Gene expression profiling can distinguish a subset of orbital pseudotumor due to GPA from sarcoid, thyroid eye disease, and controls. A subset of idiopathic orbital inflammatory disease clusters with GPA suggesting this as a possible diagnostic tool in identifying the underlying disease in idiopathic cases. Exp Mol Pathol. 2015 Oct;99(2):271-8.

Preferentially expressed genes across studies Tissue MMP9 IL-7R CD64 IL-1 TCR1 beta Leukocyte s x x x IL-1R antagonist SLC11 TLR2 TREML TLR-8 Defensin SERPINA x x x DEFA3 DEFA4 Nasal brushings IL-1 beta IL-1R type II Orbit x x x IL-1R antagonist x x TREML 1 x x x TREML 2 x DEFB4A x x x

Specific Aims: 1. Test the hypothesis that a characteristic gene expression profile distinguishes ANCA-associated vasculitis from other causes of nephritis. 2. Determine whether subsets of ANCA-associated vasculitis have distinguishable gene expression profiles at a tissue level, and explore their clinical significance. 3. Compare gene expression profiles across tissues affected by ANCAassociated vasculitis to identify commonly preserved patterns, in an attempt to identify novel treatment targets.

Study design and methods: samples Renal biopsy samples that have been collected from AAV patients Normal controls: nephrectomies of RCC, histologically normal portion of the kidney to be confirmed by renal pathology. Inflammatory control group: Interstitial nephritis samples Inflammatory glomerular control group: Lupus nephritis samples All biopsy samples must be <3 years old, older sample RNA is likely to be too degraded.

Study design and methods: clinical data Retrospective chart review: Demographic data Clinical dx (GPA/MPA) Serology (p-anca, c-anca, MPO, PR3) Treatment prior to biopsy Treatment after biopsy Treatment response/outcome Other organ involvement Pathology data: number of glomeruli involved, histopathologic description

Study design and methods: data analysis Power Analysis Power N Fold change K FDR 0.8 10 2.43 1% 0.05 0.8 10 2.01 10% 0.05 0.8 10 1.88 20% 0.05 0.8 20 1.76 1% 0.05 0.8 20 1.59 10% 0.05 0.8 20 1.53 20% 0.05 0.8 30 1.57 1% 0.05 0.8 30 1.45 10% 0.05 0.8 30 1.40 20% 0.05 N: number of samples per group K: proportion of truly differentially expressed probe sets 20 ANCA vasculitis samples gives 80% power to detect a 1.6 fold difference in gene expression if at least 10% of probes are differentially expressed. Aiming for: 20 ANCA 20 healthy control 10 lupus 10 interstitial nephritis

Statistics Training set: 70% of samples will be used to develop a training set of genes Test/validation set: remaining 30% of samples will be used to test and validate that set of genes. Principal coordinate analysis (PCA) Visualizing similarity or dissimilarity in a large complex data group All gene probes that show a significant difference between at least one disease group and the control group are used to create a 3D plot Each patient sample is represented on that 3D graph where proximity indicates greater similarity

Statistics Unsupervised hierarchical clustering analysis using a dendrogram First to see if AAV groups differently other forms of nephritis Second to distinguish MPO and PR3 subsets. Gene Set Enrichment Analysis program Identifies sets of genes with enriched expression which lends insight into the affected pathways. Data used to generate heat maps

Preliminary data 1. Do two year old FFPE renal biopsies contain adequate RNA for analysis? Pilot study of three 2-year-old renal biopsy samples sent for RNA extraction. Project samples NanoDrop 1000 BioAnalyzer Nano Chip Sample ID Delivery Date Delivery State Section/ block age Elution Volume (µl) A260 A280 260/ 280 260/ 230 Const ant RNA Concentr ation (ng/µl) RNA Yield (ng) RIN Dil. Factor RNA( µl) Water (µl) Estimat ed conc (ng/µl)* Estim ated Yield (ng) DV200 P001 1/24/17 P002 1/24/17 P003 1/24/17 FFPE ambient FFPE ambient FFPE ambient 10 micron section 20 2.4 1.3 1.9 1.6 40.0 95.7 1914.4 1.8 1 1 0 87.0 1740 43% 10 micron section 20 0.8 0.4 1.9 1.3 40.0 33.3 665.6 2.8 1 1 0 32.0 640 39% 10 micron section 20 1.4 0.7 2.0 1.9 40.0 55.1 1102.4 3.3 1 1 0 57.0 1140 37%

Preliminary Data AAV Samples: total of 49 samples identified 3 excluded because of genetic opt out, leaving 46 samples IRB amendment pending to allow us to obtain outside clinical data One renal biopsy sample where the patient has either SLE or AAV One biopsy sample with interstitial nephritis and positive ANCAs AAV Biopsy Samples Age of samples MPO positive PR3 positive Data pending Total Samples <2 years old 19 8 3 30 2-3 years old 4 4 8 16

Preliminary Data Interstitial nephritis samples: heterogeneous group Drug induced interstitial nephritis Sarcoidosis Idiopathic AIN Tubulo-intersitital nephritis and uveitis Lupus nephritis samples (pending) Control samples: Clear cell RCC nephrectomies Other cancers: oncocytoma, urothelial carcinoma Reflux nephrectomy

Strengths of this study and future directions Previous studies of the kidney have only looked at specific pathways and did not have clinical correlates. Gathering data in a hypothesis free manner, then using this data to test hypotheses. Kidney is a commonly involved organ with significant morbidity. May tell us more about mechanism of end organ damage than peripheral plasma/serum evaluation. Looking forward: comparing results with data from other tissues to identify commonly preserved pathways of disease--ultimately to find novel treatment targets.